SSG
SAGE

Summit Securities Group’s Sage Therapeutics SAGE Stock Holding History

Summit Securities Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-155
Closed -$1.12M – 449
2019
Q4 		$1.12M Buy
+155
New +$19.1K 0.08% 197

Other funds holding SAGE

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Summit Securities Group's SAGE Position: Q2 2025 in Review

Summit Securities Group sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 127 shares — an estimated $1.01K sold.

Summit Securities Group first reported a position in SAGE in Q3 2019 and held it in 2 quarters. The position peaked at $814K in Q3 2019. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

  • Summit Securities Group reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 127 Sage Therapeutics shares in Q2 2025, an estimated $1.01K.
  • Summit Securities Group first reported a position in Sage Therapeutics in Q3 2019 and held it in 2 quarters.
  • Summit Securities Group's Sage Therapeutics position peaked at $814K in Q3 2019.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.